inhoudelijk LIGHT

2.854 Posts, Pagina: « 1 2 3 4 5 6 ... 134 135 136 137 138 139 140 141 142 143 » | Laatste
abelheira
2
@Wall Street trader :
- goedkeuring filgotinib voor RA in Japan ontbreekt nog en

- wat betreft Toledo 3970 : de data fase 2 komen maar in 2021. Belangrijk hier is in hoeveel ziektedomeinen ze de fase 2 onderzoeken zullen opstarten.

- de grote verrassing (hopelijk positieve) kan er komen voor GLPG1972.
Niet meer actief32
9
De NOVESA studie van Galapagos met GLPG1690 (Autotaxin > ATX) in patiënten met scleroderma (SSc) zal snel volgen.

Primaire eindpunt 24 weken.

> week 49 2019 klaar met rekruteren + 24 weken behandeling =
> week 21 2020 laatste dosering (week 18 mei)


Orphan drug status = weesgeneesmiddel voor SSc = markt ter grootte van + 100.000 patiënten en nagenoeg geen werkzame medicijnen.

Wetenschappelijke abstracts.


Conclusie van andere autotaxin inhibitor > preklinische studie in SSc

We demonstrate that ATX has an important role in SSc fibrosis. Pharmacologic inhibition of ATX with a novel inhibitor, PAT-048, attenuated dermal fibrosis and IL-6 expression. Knock-down of IL-6 in fibroblasts in vitro abrogated LPA-induced ATX expression, suggesting an autocrine loop for ATX/LPA/IL-6 signaling. Both ATX and IL-6 are increased in SSc skin compared to healthy controls, and LPA-induced IL-6 and IL-6-induced ATX expression are increased in SSc fibroblasts, further supporting an ATX/LPA/IL-6 autocrine loop in SSc. Targeting ATX may thus be an effective new therapeutic strategy for SSc fibrosis.

acrabstracts.org/abstract/autotaxin-i...
Broer Konijn
0
@WST

You’re absolutely right. It’s just frustrating to see a stock getting hammered for a longer period when you know the value is there......

Basic investing skill is patience. It’s just not my best feature.....
I can’t add Gala stock to my portfolio. I am invested up to my eyeball’s...

It’s easy to take Gala’s performance for granted and consider it to be normal. It isn’t.....

Thanks for the excellent overview and have a good one.

Cheers Elliot Rabbit
C200
4
Leuk dat bij Onno alles draait om de Galapagos eilanden. Zo zijn verschillende studies vernoemd naar eilanden binnen de Galapagos groep. O.a. Pinta en Isabela.
En geloof het of niet, Genovesa (De nieuwe Filgotinib man bij Gilead) is ook de naam van een Galapagos eiland,

Gilead en Galapagos hebben een nieuwe site: In Darwins Footsteps. Charles Darwin was een wetenschapper (ontdekkingsreiziger) die met zijn schip The Beagle (IEX alias van Onno is Beagle06) de Galapagoseilanden aandeed in 1835.

hosted.bmj.com/in-darwins-footsteps
Wall Street Trader
2
Galapagos' stermiddel filgotinib helpt ook patiënten met psoriatische artritis

DAVID ADRIAEN Vandaag om 00:39

Het Mechelse biotechbedrijf zegt dat zijn reumapil filgontinib ook langdurig werkt als behandeling voor de nauw verwante ziekte psoriatische artritis.

Op het jaarlijkse reumatologencongres Eular stelde Galapagos en zijn Amerikaanse partner Gilead nieuwe analyses voor van studies met filgotonib bij patiënten die lijden aan psoriatische artritis. De bedrijven hadden vorig jaar al een studie voorgelegd waaruit bleek dat het kandidaat-medicijn werkt bij een grote groep patiënten.

Nu blijkt uit een opvolgstudie van een jaar dat het filgotinib ook op langere termijn werkzaam is en veilig is. Walid Abi-Saad, de medisch directeur van Galapagos, onderstreept dat 'het medicijn snel werkt om de kenmerken van ontsteking te verminderen'. Een grotere studie moet dit nu nog bevestigen, maar Galapagos gaf eerder aan dat Gilead die Fase 3-studie Penguin gepauzeerd heeft door de corona-pandemie.

Blockbuster

Psoriatische artritis is een van de 10 aandoeningen waarvoor filgotinib wordt getest, naast de hoofdindicatie reumatische artritis. Voor die laatste aandoening zijn alle grote patiëntenproeven afgerond. De dossiers liggen bij de Europese en Amerikaanse geneesmiddelenautoriteiten klaar om groen licht te krijgen. Zij zullen nog dit jaar een oordeel vellen over de markttoelating van deze mogelijke blockbuster.

De inzet bij bijkomende ziektes moeten helpen om de hooggespannen verwachtingen van beleggers en analisten voor filgotinib te vervullen. Vorige maand werd het aandeel Galapagos wat afgestraft na testresultaten met filgotinib bij de darmontsteking colitus ulcerosa. Die data waren op zich goed, maar minder overtuigend dan soms gehoopt.

www.tijd.be/ondernemen/farma-biotech/...
Wall Street Trader
1
The information contained in this website is directed exclusively to professionals authorised to prescribe or dispense medicinal products. Thus, the information contained in this website requires specialised training and scientific background for its correct interpretation.

learnjakstat.com/ra/pathogenesis-of-i...

Experts discuss RA pathogenesis


Introducing the JAK-STAT pathway

learnjakstat.com/video/KOL-KevinWinth...

The role of cytokines in the JAK-STAT pathway

learnjakstat.com/video/KOL-PaulEmery.mp4

Regulation of the immune response by the JAK family proteins

learnjakstat.com/video/KOL-JanetPope.mp4

Cytokines and JAK family proteins work together to mediate specific cell responses

learnjakstat.com/video/KOL-PeterTaylo...

To follow our progress and receive the latest content on RA, including valuable teaching materials, enter your details below.

learnjakstat.com/ra/sign-up/

lmr
1
quote:

C200 schreef op 6 juni 2020 09:51:


Leuk dat bij Onno alles draait om de Galapagos eilanden.


Ook goed om te zien dat Gilead de ruimte blijft geven om deze visie door te zetten en samen met Galapagos het verhaal van de reis beschrijft op de manier dat Galapagos dit wil delen.
Wall Street Trader
1
Follow Gilead and Galapagos on Youtube.

We at Gilead and Galapagos have forged a new partnership with complementary strengths, a passion for innovation, and a shared vision of transforming the treatment of inflammatory diseases. "In Darwin's footsteps: Adaptation through innovation in RA" is a Gilead and Galapagos organised and funded symposium taking place during the EULAR 2020 E-Congress, looking at the great progress that has been made in the management of rheumatoid arthritis and the improvements that are continually evolving.

Introduction to “In Darwin's footsteps Adaptation through innovation in RA” the Gilead and Galapagos organised and funded symposium that is available to EULAR 2020 registrants. Together we look to a brighter future in the management of rheumatoid arthritis.

www.youtube.com/watch?v=68F2W3CZNPI

Find Symposium details here:

hosted.bmj.com/in-darwins-footsteps

GILEAD, GALAPAGOS, AND INFLAMMATION

www.raneedsinnovation.com/our-commitm...
Lama Daila
0
www.bloomberg.com/news/articles/2020-...

AstraZenica Approaches Gilead About Potential Merger

AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record, Bloomberg News reports.
Lama Daila
3
www.bloomberg.com/news/articles/2020-...

AstraZeneca Is Said to Approach Gilead About Potential Merger

AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record.

The U.K.-based firm contacted Gilead last month about a possible tie-up, the people said, asking not to be identified because the details are private. AstraZeneca didn’t specify terms for any transaction, they said. While Gilead has discussed the idea with advisers, no decisions have been made on how to proceed and the companies aren’t in formal talks, the people added.

AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease. Gilead, worth $96 billion at Friday’s close, is the creator of a drug that’s received U.S. approval for use with coronavirus patients.

Gilead is not currently interested in selling to or merging with another big pharmaceutical company, preferring instead to focus its deal strategy on partnerships and smaller acquisitions, the people said.

A representative for Gilead couldn’t be reached for comment outside of regular business hours. A spokesman for AstraZeneca said the company doesn’t comment on “rumors or speculation.”

Coronavirus Treatment

Gilead’s share price has climbed 18% this year as its antiviral drug for Covid-19, remdesivir, worked its way through clinical trials. The stock is still more than a third lower than its 2015 highs. The Foster City, California-based company has seen a steady decline in sales in its hepatitis C franchise and is trying to reinvigorate its drug-development pipeline.

Remdesivir, which has an emergency use authorization from the U.S. Food and Drug Administration, has been shown in some early studies to shorten hospital stays for people with Covid-19. SVB Leerink recently forecast that sales of the drug may reach $7.7 billion in 2022.

Gilead has been dispensing early rounds of the drug for free, leading some investors to question how the company plans to make money from it in the future. Chief Executive Officer Daniel O’Day has said the company may spend $1 billion on the treatment this year alone.

AstraZeneca, led by CEO Pascal Soriot, is helping to manufacture a Covid vaccine developed at the University of Oxford. The U.S. has pledged as much as $1.2 billion to support the efforts as part of Operation Warp Speed, a push to secure vaccines for America. The shot is expected to enter phase III clinical trials in June.

Deal Slump

Health-care dealmaking has been a rare bright spot as the global pandemic and resulting lockdowns have doused the market for mergers and acquisitions. Global M&A volumes are down about 45% this year, according to data compiled by Bloomberg, and announced deals have been falling apart at a steady pace.

Excluding minority investments, dealmaking in April and May barely topped $100 billion in total, the data show, the lowest two-month period in at least 22 years.

AstraZeneca is no stranger to large-scale, politically sensitive M&A. In 2014 it fended off a $117 billion approach from Pfizer Inc., a deal that attracted attention from U.S. lawmakers as it would have allowed New York-based Pfizer to lower its tax bill by redomiciling in the U.K.

Its shares are up 11% since the start of the year, boosted by positive data from trials of its blockbuster lung cancer drug Tagrisso.
Wall Street Trader
6
Stanford researcher Genovese joins Gilead to lead NASH, arthritis programs

Gilead and partner Galapagos are awaiting an FDA decision on their arthritis drug filgotinib, which was filed with the FDA late last year.

This is a major drug for Gilead, which spent $5 billion on a deep pipeline deal with Galapagos last year. Gilead has long had a stake in the late-phase JAK1 inhibitor filgotinib, with recent data readouts showing the med is better than methotrexate alone while suggesting it has an edge over AbbVie’s Humira, the aging blockbuster rheumatoid arthritis incumbent.

Results shared to date suggest Gilead has enough positive evidence to get filgotinib approved. The harder question is whether the evidence is strong enough to get filgotinib a cleaner label than its rivals or otherwise give it an advantage that translates into the hoped-for blockbuster sales.

The safety of filgotinib is a particular source of ongoing uncertainty. Gilead and Galapagos think filgotinib is free from some of the safety problems that blighted Pfizer's Xeljanz and Eli Lilly's Olumiant and hit multiple members of the JAK family.

However, AbbVie’s Rinvoq, which, like filgotinib, is specific to JAK1, received a black box warning when it won FDA approval earlier this year. If approved, this would be the company’s first medicine to treat an inflammatory disease.

Genovese, who is now the company's senior vice president of inflammation, will oversee this drug’s development and has overall responsibility for clinical work of its experimental portfolio of treatments for inflammatory conditions.

“We are very pleased to welcome Mark to Gilead; he is one of the leading researchers and clinicians in the fields of immunology and rheumatology, and we will benefit tremendously from his expertise as we seek to bring forward new treatments that improve care for patients with rheumatoid arthritis, inflammatory bowel disease and other debilitating conditions,” said Merdad Parsey, M.D., Ph.D., chief medical officer at Gilead.

“Gilead has a long history of transforming care for people with serious illnesses, such as HIV and viral hepatitis, and I’ve watched as the company has worked over the past several years to add programs, resources and individuals to bring that same scientific rigor and innovation to patients with inflammatory diseases, where doctors and patients are so much in need of better treatment options,” added Genovese.

“In my prior academic role, I had the opportunity to work with Gilead as the company began to grow its work in inflammatory diseases, and I’m excited to join the talented team. I look forward to the progress we will make together to transform care for patients.

www.fiercebiotech.com/biotech/stanfor...
MrBiggy
0
Het rotsvaste vertrouwen in Filgotinib en zeker ook GLPG1690 zal zich verder in (doorlopend) rendement gaan uitdrukken. Ik meen dat Galapagos de enige nog is die met IPF (in zo'n vergevorderd stadium) is.
MrBiggy
0
De "vraag" is natuurlijk waarom Gilead enorm heeft geïnvesteerd in Galapagos
en hoe het komt dat de grote reuzen altijd op zoek zijn naar nieuwe uitdagingen
(zeg maar de financiële positieve prikkels)...
grote bedrijven weten dat het niet makkelijk is om een "nieuw wiel uit te vinden"...

Een mooi dynamisch bedrijf als Galapagos heeft deze prikkels allemaal in huis!
abelheira
0
1. Weet iemand of AZ ook in de running was toen de overeenkomst tot stand kwam met Gilead?
2. Een tijdje geleden werd er over gespeculeerd wanneer Gilead warrant B zou uitoefenen? Toen werd er geopperd dat dit waarschijnlijk zou gebeuren na goedkeuring filgo in de VS. Denken jullie dit nog steeds?
MrBiggy
1
Hier nog een positief recent nieuwsberichtje van
The Wall Street Journal... zag hem nog niet op dit draadje..

PRESS RELEASE
NEW ANALYSES OF PHASE 2 EQUATOR CLINICAL PROGRAM SUPPORT DURABLE EFFICACY OF FILGOTINIB IN PSORIATIC ARTHRITIS
June 5, 2020 4:06 pm ET

www.wsj.com/articles/PR-CO-20200605-9...
P.iddybull
2
Mr Biggy : gelieve maanddraad te gebruiken voor uw 3 type posts : hier enkel inhoudelijk light !
voda
2
e-therapeutics en Galapagos werken samen

FONDS KOERS VERSCHIL VERSCHIL % BEURS
Galapagos
180,75 0,00 0,00 % Euronext Amsterdam

(ABM FN-Dow Jones) e-therapeutics en Galapagos gaan samenwerken om nieuwe behandelingen te ontwikkelen voor idiopathische longfibrose. Dit maakte het Britse biotechbedrijf woensdagochtend bekend.

Deze samenwerking combineert de expertise van e-therapeutics op het gebied van netwerkbiologie en silico-fenotypische screening met de diepgaande kennis van Galapagos op het gebied van IPF en fibrose.

Galapagos betaalt e-therapeutics voor de samenwerking, onder meer wanneer bepaalde mijlpalen zijn behaald.

Door: ABM Financial News.
info@abmfn.nl
Redactie: +31(0)20 26 28 999

© Copyright ABM Financial News B.V. All rights reserved.
Kelewan
2
Het hele persbericht:

Collaboration with Galapagos to discover new therapeutic strategies for the treatment of idiopathic pulmonary fibrosis and other fibrotic conditions


Oxford, UK, 10th June 2020: e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company") today announces that it has entered a collaboration agreement with Galapagos NV ("Galapagos") to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF) and potentially in other fibrotic indications. e-therapeutics will continue to be free to explore, both internally and with additional partners, all other pathways involved in IPF and fibrosis.


This collaboration combines e-therapeutics' expertise in network biology and in silico phenotypic screening with Galapagos' deep knowledge of IPF and fibrosis. e-therapeutics will apply its proprietary Network-driven Drug Discovery (NDD) platform and know-how to identify new strategies to modulate a specific pathway of interest to Galapagos, selecting potentially clinically relevant compounds for the treatment of IPF and fibrosis. As part of the collaboration, e-therapeutics will be responsible for all computational activities and Galapagos will perform all experimental testing.



Under the terms of the agreement, e-therapeutics will receive upfront and near-term payments material to the cash position of the Company. e-therapeutics is also eligible to receive pre-clinical and clinical development and commercial milestone payments.

In the United States, 30-40,000 cases of IPF are diagnosed each year. IPF is associated with a progressive loss of lung function and median survival without therapy is limited to between two and three years. Currently available treatments slow disease progression but prognosis remains poor and IPF is the leading cause of lung transplantation. There is a high unmet need for novel and well-tolerated agents able to reduce lung function decline and improve and prolong patients' lives. Other fibrotic conditions, such as those affecting the liver or the kidneys, affect a significant proportion of the population worldwide and also represent urgent medical needs.


Ali Mortazavi, Executive Chairman of e-therapeutics, commented: "We look forward to working with Galapagos on this project in areas of clear unmet medical need such as IPF and fibrosis. This collaboration provides additional validation of our platform and its applications in drug discovery and development. Our platform is scalable and can be applied to all areas of biology, providing an engine for diverse drug discovery projects and enabling us to help partners in numerous ways. This is our third collaboration with a leading biopharmaceutical company, and we remain in business development discussions for both NDD and our functional genomics platform, GAINs."
Wall Street Trader
3
Some more information about e-Therapeutics.

They are an Oxford, UK-based business with a revolutionary computer-based platform and a unique network-driven drug discovery ("NDD") methodology which allows them to discover novel and better drugs faster.

www.youtube.com/watch?v=wQFpTtuzrgA

Network-driven drug discovery

www.etherapeutics.co.uk/media/1211/dt...

A Great collaboration deal for Galapagos!

tools.euroland.com/tools/PressRelease...

2.854 Posts, Pagina: « 1 2 3 4 5 6 ... 134 135 136 137 138 139 140 141 142 143 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 4 aug 2020 16:24
Koers 161,800
Verschil -2,250 (-1,37%)
Hoog 166,100
Laag 160,550
Volume 244.186
Volume gemiddeld 423.135
Volume gisteren 287.425